Clinical trial in Ireland challenges beliefs about Ozempic and similar new obesity treatments

newsnationnow.com

A new study suggests semaglutide (Ozempic, Wegovy) can effectively treat obesity, with higher dosages and longer use leading to more weight loss. However, it's not a 'magic fix' and requires lifestyle changes. Ozempic, originally for Type 2 diabetes, gained popularity for weight loss, leading to shortages. Despite risks like bone density issues, it's seen as a scientifically backed treatment for obesity.

mychamplainvalley.com

A study suggests Ozempic, a diabetes drug, can aid long-term weight loss in obese patients, with higher dosages and consistent use showing better results. However, it requires lifestyle changes and is not a 'magic fix.' Ozempic's popularity surged due to social media, leading to shortages, but it remains a scientifically backed treatment for obesity.

abc27.com

A new study suggests Ozempic, a diabetes drug, can effectively treat obesity, with higher dosages and longer use leading to more weight loss. However, it requires lifestyle changes and is not a 'magic fix.' The drug's popularity has led to shortages, and while it is beneficial, it also poses risks like bone density loss and potential overdose.

medicalupdateonline.com

A study at St Vincent's University Hospital challenges the belief that weight loss medications like Ozempic, Wegovy, or Monjaro work solely by promoting satiety. The randomized controlled trial, led by Professor Donal O'Shea, found a strong relationship between the increase in metabolic activity caused by GLP-1 treatment and weight loss, with low metabolic activity prior to treatment showing the most benefit.